SCHEMBL2770134

SCHEMBL2770134

CCOC(=O)CCc1ccc(C(F)(F)F)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.52
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 1/20 0.44
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
DAO P14920 1/20 0.43
EPHX2 P34913 1/20 0.41
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
MCHR1 Q99705 1/20 0.40
ALDH1A1 P00352 2/20 0.40
FPR2 P25090 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3936853 0.92 POLB (0.50) POLBGAASMN1; SMN2HPGDL3MBTL1
SCHEMBL19215825 0.83 NPC1 (0.52) POLBSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL3299826 0.81 CYP4F2 (0.46) POLBHPGDL3MBTL1MAPTKDM4E
SCHEMBL16283828 0.81 CYP4F2 (0.49) GAASMN1; SMN2HPGDL3MBTL1MAPT
SCHEMBL2080801 0.80 CYP4F2 (0.47) GAAHPGDL3MBTL1MAPTKDM4E
SCHEMBL2771208 0.80 L3MBTL1 (0.53) POLBGAAL3MBTL1MAPTCYP4F2
SCHEMBL24419456 0.79 L3MBTL1 (0.44) POLBGAASMN1; SMN2HPGDL3MBTL1
SCHEMBL29551173 0.79 KMT2A (0.51) NPC1RAB9AKDM4EKMT2ADAO
SCHEMBL16278189 0.78 CYP4F2 (0.46) HPGDMAPTRAB9AKDM4EKMT2A
SCHEMBL15136243 0.78 CYP4F2 (0.46) GAASMN1; SMN2HPGDL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910357-B1 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LTD (GB) 2010-04-14 EP disclosed
US-20090163534-A1 Indolizine Derivatives ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 US disclosed
EP-1910357-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2008-04-16 EP disclosed
WO-2006136859-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163534-A1 Indolizine Derivatives HRH4, HRH2, NR1H2 POLB 4250/4885GAA 4797/4885SMN1; SMN2 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.